Kineta Income After Taxes 2014-2024 | KANT
Kineta income after taxes from 2014 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Kineta Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-14 |
| 2022 |
$-63 |
| 2021 |
$-12 |
| 2020 |
$-57 |
| 2019 |
$-31 |
| 2018 |
$-62 |
| 2017 |
$-59 |
| 2016 |
$-37 |
| 2015 |
$-25 |
| 2014 |
$-16 |
| 2013 |
$-16 |
Kineta Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$-3 |
| 2024-03-31 |
$-10 |
| 2023-12-31 |
$-3 |
| 2023-09-30 |
$-5 |
| 2023-06-30 |
$0 |
| 2023-03-31 |
$-6 |
| 2022-12-31 |
$-47 |
| 2022-09-30 |
$-6 |
| 2022-06-30 |
$-6 |
| 2022-03-31 |
$-5 |
| 2021-12-31 |
$17 |
| 2021-09-30 |
$-10 |
| 2021-06-30 |
$-10 |
| 2021-03-31 |
$-9 |
| 2020-12-31 |
$-37 |
| 2020-09-30 |
$-6 |
| 2020-06-30 |
$-7 |
| 2020-03-31 |
$-7 |
| 2019-12-31 |
$16 |
| 2019-09-30 |
$-13 |
| 2019-06-30 |
$-20 |
| 2019-03-31 |
$-14 |
| 2018-12-31 |
$-17 |
| 2018-09-30 |
$-18 |
| 2018-06-30 |
$-15 |
| 2018-03-31 |
$-11 |
| 2017-12-31 |
$-13 |
| 2017-09-30 |
$-14 |
| 2017-06-30 |
$-17 |
| 2017-03-31 |
$-15 |
| 2016-12-31 |
$-9 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-8 |
| 2015-12-31 |
$-6 |
| 2015-09-30 |
$-7 |
| 2015-06-30 |
$-7 |
| 2015-03-31 |
$-6 |
| 2014-12-31 |
|
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
